U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell LymphomaContributed by: Business WireLogoImagesBeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the Princeton West Innovation Campus in Hopewell, N.J.TagsResearchFDAClinical TrialsCardiologyBiotechnologyHealthPharmaceuticalScienceOncologyBRUKINSA, zanubrutinib, ASH Annual Meeting
